Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.19M | $4.03M | $1.46M | $1.17M | $8.03M | $6.78M | $7.42M | $4.45M | $5.04M | $4.86M |
| Revenue growth | — | 26.3% | -63.6% | -20.2% | 587.3% | -15.6% | 9.4% | -40.0% | 13.3% | -3.7% |
| Operating income | -$18.6M | -$14.3M | -$16.9M | -$19.4M | -$12.8M | -$35.5M | -$14.0M | -$6.10M | -$3.65M | -$2.50M |
| Operating margin | -584.1% | -355.6% | -1152.3% | -1657.9% | -159.0% | -524.0% | -188.8% | -137.0% | -72.3% | -51.5% |
| Net income | -$19.6M | -$15.7M | -$13.5M | -$28.8M | -$4.66M | -$14.7M | -$15.4M | -$14.0M | -$7.04M | -$2.34M |
| Net margin | -615.6% | -390.1% | -920.8% | -2464.1% | -57.9% | -216.2% | -207.3% | -313.9% | -139.5% | -48.1% |
| EPS (diluted) | -$8.85 | -$7.28 | -$3.58 | -$4.53 | -$0.47 | -$27.56 | -$25.65 | -$11.29 | -$5.17 | -$1.71 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.1M | -$14.0M | -$13.6M | -$17.2M | -$30.2M | -$25.9M | -$14.0M | -$15.3M | -$9.63M | -$4.74M |
| Capital expenditures | $231K | $79.0K | $250K | $1.48M | $2.33M | $1.01M | $72.0K | $5.00K | $16.0K | $0.00 |
| Free cash flow | -$17.3M | -$14.0M | -$13.9M | -$18.7M | -$32.6M | -$26.9M | -$14.0M | -$15.3M | -$9.64M | -$4.74M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.01M | $9.13M | $12.0M | $8.42M | $14.0M | $28.7M | $20.6M | $6.52M | $4.24M | $259K |
| Total assets | $56.6M | $16.6M | $24.0M | $32.6M | $47.3M | $43.9M | $28.9M | $19.7M | $13.5M | $6.55M |
| Total liabilities | $34.4M | $8.56M | $11.2M | $24.2M | $18.8M | $12.7M | $8.02M | $7.00M | $7.29M | $2.41M |
| Long-term debt | $25.1M | $0.00 | $0.00 | $107K | $2.10M | $0.00 | — | — | — | — |
| Shareholders' equity | $22.2M | $8.01M | $12.8M | $8.32M | $28.6M | $31.2M | $20.9M | $12.7M | $6.22M | $4.14M |
| Retained earnings | -$152M | -$167M | -$178M | -$207M | -$212M | -$226M | -$258M | -$272M | -$279M | -$281M |
| Shares (wtd avg diluted) | 2.22M | 2.13M | 4.77M | 8.65M | 13.5M | 532K | 599K | 1.24M | 1.36M | 1.37M |
Every figure is extracted from Arcadia Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.